thalidomide has been researched along with losartan potassium in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.96) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 29 (56.86) | 29.6817 |
| 2010's | 20 (39.22) | 24.3611 |
| 2020's | 1 (1.96) | 2.80 |
| Authors | Studies |
|---|---|
| Brede, HD; DeKlerk, JN; Groenewald, JH; Mirand, EA; Murphy, GP; Schoonees, R; van Zyl, JJ; Weber, HW | 1 |
| Greipp, PR | 1 |
| Desikan, R; Jagannath, S; Li, Z | 1 |
| Bisceglia, M; Carella, AM; Falcone, A; Matera, R; Musto, P; Sanpaolo, G | 1 |
| Gastl, G; Stauder, R; Steurer, M; Sudmeier, I | 1 |
| Finelli, C; Isidori, A; Malagola, M; Mele, A; Piccaluga, PP; Visani, G | 1 |
| Gisslinger, H; Kees, M | 1 |
| Mehta, J; Pichardo, D; Rosen, S; Singhal, S | 1 |
| Musto, P | 1 |
| Barbui, T; Comotti, B; Crippa, C; Elice, F; Galli, M; Rodeghiero, F | 1 |
| Aul, C; Boultwood, J; Germing, U; Giagounidis, AA; Wainscoat, JS | 1 |
| Alymara, V; Amalia, V; Aristeidis, C; Benetatos, L; Bourantas, KL; Chaidos, A; Konstantinos, BL; Leonidas, B; Vasiliki, A; Vassou, A | 1 |
| Bodenizza, C; Falcone, A; Musto, P; Sanpaolo, G | 1 |
| DeLap, RJ; Knight, R; Zeldis, JB | 1 |
| Nimer, SD | 1 |
| Thomas, ML | 1 |
| Baker, AF; Bellamy, W; Green, S; List, AF | 1 |
| Goss, TF; Hellström-Lindberg, E; Jädersten, M; Knight, R; List, AF; Schaefer, C; Szende, A; Totten, PJ | 1 |
| Steensma, DP; Tefferi, A | 1 |
| Baumann, MA; Chennuru, S | 1 |
| Schiffer, CA | 1 |
| Cervantes, F | 1 |
| Adès, L; Aljassem, L; Bouscary, D; Brechignac, S; Daniel, MT; de Botton, S; Dombret, H; Dreyfus, F; Fenaux, P; Giraudier, S; Kelaidi, C; Lepelley, P; Leroux, G; Mannone, L; Park, S; Picard, F; Raynaud, S; Stamatoullas, A; Vey, N | 1 |
| Ohyashiki, K | 1 |
| Cosler, LE; Ferro, SA; Greenberg, PL; Lyman, GH | 1 |
| Hellström-Lindberg, E; Jädersten, M | 1 |
| Stone, RM | 1 |
| Kurtin, SE; List, AF | 1 |
| Ishikawa, T | 1 |
| de Wolf, JT; Huls, G; Mulder, AB; Rosati, S; van de Loosdrecht, AA; Vellenga, E | 1 |
| Lachs, MS; Ritchie, EK | 1 |
| Galili, N; Raza, A | 1 |
| Fenaux, P; Garcia-Manero, G | 1 |
| Anaissie, EJ; Bailey, C; Barlogie, B; Coleman, EA; Coon, SK; Goodwin, JA; Kennedy, RL; Lockhart, KD; Stewart, CB | 1 |
| Alexander, MP; Méndez, GP; Nasr, SH; Rennke, HG; Watson, DC | 1 |
| Altés, A; De Paz, R; del Cañizo, C; López Arrieta, JM | 1 |
| Gonçalves, R; Lopes, J; Macedo, G; Sobrinho Simões, M; Vilas-Boas, F | 1 |
| Chen, N; Komrokji, RS; Lancet, JE; List, AF; Lush, R; Paleveda, J; Saba, HI; Swern, AS | 1 |
| Anaissie, EJ; Coleman, EA; Coon, SK; Enderlin, C; Goodwin, JA; Kennedy, R; Lockhart, K; McNatt, P; Richards, K; Stewart, CB | 1 |
| Chen, S; Chen, Z; Liu, D; Pan, J; Wu, N; Zhu, F; Zhu, M | 1 |
| Tohyama, K | 1 |
| Meers, S | 1 |
| Birgegård, G | 1 |
| Usuki, K | 1 |
| Banos, A; Benramdane, R; Beyne-Rauzy, O; Bordessoule, D; Bouabdallah, K; Caillot, D; Chevret, S; Cheze, S; Chouffi, B; Cony-Makhoul, P; De Renzis, B; Delaunay, J; Dreyfus, F; Fenaux, P; Fontenay, M; Gardin, C; Gruson, B; Guerci-Bresler, A; Guilhot, F; Gyan, E; Isnard, F; Kosmider, O; Laribi, K; Legros, L; Lejeune, J; Maloum, K; Nimuboma, S; Petit, R; Preudhomme, C; Renneville, A; Rose, C; Salanoubat, C; Sanhes, L; Sardnal, V; Slama, B; Soussain, C; Stamatoullas, A; Taksin, AL; Tertian, G; Toma, A; Wattel, E; Wickenhauser, S | 1 |
| Beyne-Rauzy, O; Chesnais, V; Chevret, S; Delaunay, J; Dreyfus, F; Dumont, F; Fenaux, P; Fontenay, M; Kosmider, O; Lambert, J; Lejeune, J; Passet, M; Preudhomme, C; Raimbault, A; Renneville, A; Rose, C; Solary, E; Stamatoullas, A; Toma, A | 1 |
| Buckstein, R; Rezmovitz, J; Wells, RA | 1 |
| Ades, L; Auberger, P; Basiorka, AA; Cluzeau, T; Fenaux, P; Irvine, B; List, A; Maciejewski, J; Masala, E; McGraw, KL; Santini, V; Wei, S | 1 |
| Giagounidis, A | 1 |
| Abayaweera, G; Abou-Taleb, HA; AbouElhassan, KM; AbouTaleb, HA; Adair, LS; Adams, E; Addison, O; Addy, I; Akhtar, N; Alten, B; Anesini, J; Añez, R; Angaridis, PA; Aouba, A; Arakawa, K; Aumeeruddy-Elalfi, Z; Bao, LP; Basu, E; Bayraktar, E; Bekkelund, CS; Bell, J; Beraldo, H; Bermúdez, V; Betenbaugh, MJ; Bhattacharya, R; Bienvenu, B; Bolzoni, M; Bootz, F; Borja, JB; Bove, DG; Bowden, ME; Bradsher, C; Brockstedt, D; Brothers, RM; Buschauer, A; Calandriello, L; Caporossi, A; Carba, DB; Carratalà, J; Castella, B; Caviezel, D; Ceccato, R; Charalambidis, G; Charisiadis, A; Chattopadhyay, P; Chen, Q; Chen, W; Chen, Y; Chen, YT; Chen, ZJ; Chen, ZY; Cheng, MA; Cheng, ZB; Cherevko, S; Cheung, IY; Cheung, NV; Chiappini, A; Chiu, YL; Choi, IG; Chough, S; Chung, CY; Cobb, A; Colotto, A; Continentino, MA; Cook, AJMC; Costa, F; Coutsolelos, AG; Cuperus, N; Curtis, BM; Davenport, AJ; de Boysson, H; Dela, F; Deng, XP; Deshayes, S; Dhara, K; Dietrich, D; Dietrich, J; Dilhari, A; Ding, R; Ding, Y; Dirè, S; Dohlmann, TL; Dotsenko, A; Doubrovina, E; Du, K; Du, ZJ; Duvic, M; Eastman, A; Eliakim-Raz, N; Elz, S; Emile, JF; Emmerling, C; Engelhard, MH; Eriksson, JG; Etzold, BJM; Faini, AC; Falsini, B; Farmer, E; Fei, JJ; Ferreira, IP; Föttinger, K; Franconieri, F; Fryda, NJ; Fuentes, I; Galateau-Sallé, F; Ganguly, M; Gani, BA; Gao, X; Gao, XF; Gao, XJ; García-Mendiola, T; Garg, A; Gascon, J; Gayani, B; Gevensleben, H; Gilbert, M; Giudiceandrea, A; Giuliani, N; Gocmen, AY; Goldman, DA; Goltz, D; Gombert, AK; Gomila, A; Goodwin, P; Górnicki, K; Gostin, PF; Graterol, M; Gremillet, C; Grier, S; Grün, AL; Gusakov, A; Halldórsdóttir, HR; Han, L; Han, Z; Hävecker, M; Helge, JW; Heo, K; Hernández, JD; Hindsø, M; Holmen Olofsson, G; Hong, CE; Hong, J; Horenstein, AL; Hosenally, M; Hruz, P; Hsu, HL; Hsu, KC; Hu, SF; Hu, Y; Huang, K; Huang, S; Huang, WH; Humaira, A; Hung, CF; Hung, WS; Huo, XK; Huvinen, E; Idorn, M; Ignatyev, K; Im, WT; Ismaël, IS; Jakobsson, JG; Janaszek-Mańkowska, M; Jeong, GT; Ji, L; Ji, X; Jiang, Y; Jo, IH; Jo, SH; Johnson, AC; Johnson, LE; Kadirvelu, K; Kahnt, A; Kaleta, A; Kamiya, T; Kang, DH; Kang, XH; Kashiwagi, T; Katayama, E; Kawachi, N; Keller, M; Kellermann, L; Khan, T; Khan, ZA; Kharshoum, RM; Khim, JS; Kikuchi, M; Kim, BS; Kim, DS; Kim, DW; Kim, JH; Kim, JJ; Kim, JU; Kim, SK; Kim, WS; Kimura, J; Kiss, C; Knop-Gericke, A; Kobayashi, S; Koivusalo, SB; Kolar, E; Kottegoda, N; Kramer, K; Kristiansen, G; Kruger, AA; Kumar, S; Kumar, V; Kumarage, S; Kursungoz, C; Kushner, BH; Kuwahara, F; Kuzawa, C; Kwon, BO; Landsberg, J; Larsen, S; Lauer, P; Le Luduec, JB; Lee, DW; Lee, H; Lee, HY; Lee, JW; Lee, MJ; Lee, SW; Lefrançois, P; Leibovici, L; Leong, KK; Leong, M; Li, B; Li, D; Li, G; Li, J; Li, YZ; Liang, JH; Liang, X; Liens, A; Ligorio, G; Lin, JD; Lindholm, MG; Liou, MJ; List-Kratochvil, EJW; Litvinov, IV; Liu, F; Liu, S; Liu, Y; Liu, Z; Lohar, S; Lopes, MTP; Lorenzo, E; Lu, X; Lukashuk, L; Lukens, WL; Luo, HR; Luo, L; Luttik, MAH; Ma, Y; MacGowan, A; Mahomoodally, MF; Maissen, S; Malavasi, F; Malhotra, M; Mallik, S; Manna, D; Mans, R; Marangoni, D; Marimpietri, D; Marques, F; Marques, WL; Marsaa, K; Martin Silva, N; Martinez, A; Martínez, MS; Massaia, M; Mayrhofer, KJJ; McDade, T; McNeel, DG; Met, Ö; Micalizio, GC; Modak, S; Morandi, F; Moreau, L; Morla, S; Morrell, AP; Morris, S; Mubarak, Z; Muchlisin, ZA; Munoz, M; Nagao, Y; Nakama, T; Nakamura, H; Nakano, T; Nardi, MV; Nasirian, A; Nelson, MD; Netchiporouk, E; Ni, X; Niess, JH; Nijenhuis, JM; Nikolaou, V; O'Connor, BJ; O'Reilly, RJ; Odobel, F; Ohata, C; Ohyama, B; Olivar, LC; Ordoñez, MG; Ostrovnaya, I; Palmar, J; Panda, S; Pandiyarajan, S; Park, B; Park, H; Park, JH; Park, S; Pasquali, L; Patik, JC; Pearce, CI; Peele, ME; Peng, S; Perera, IC; Petty, JT; Pidko, EA; Pinheiro, CB; Pistoia, V; Pita, M; Planchat, A; Plass, F; Pockes, S; Pradhan, N; Premasudha, P; Pronk, JT; Provost, N; Pujol, M; Qi, P; Qiu, J; Qiu, Z; Quan, J; Quaranta, A; Ra, CH; Rameshan, R; Ranglack, DH; Rausch-Fan, X; Rieger, E; Rivas, JR; Roberts, SS; Rocha, WR; Rodrigues, GLS; Rojas, J; Roy, P; Rozhkova, A; Rufo, S; Rupprechter, G; Saeui, CT; Saha, A; Sakai, M; Salazar, J; Salem, HF; Salgarello, T; Samarakoon, SR; Sandau, C; Sandbeck, DJS; Santos, AF; Santos, VG; Sara, Y; Saslow, SA; Sasseville, D; Sato, S; Sauer, JD; Schlögl, R; Schweiger, MJ; Shashkov, I; Shaw, E; Shen, WQ; Shim, J; Shu, J; Singh, C; Sinha Babu, SP; Sinitsyn, A; Sinitsyna, O; Skadborg, SK; Song, Q; Song, W; Stach-Lempinen, B; Stoddart, M; Stoica, M; Street, SR; Sukwong, P; Sun, CP; Sun, J; Sunwoo, IY; Suresh, S; Szécsényi, Á; Takahashi, T; Takeda, S; Tang, D; Tas, ST; Tebé, C; Teixeira, LR; Teixidor, F; Terrier, B; Teschner, D; Tetzlaff, MT; Theisen, E; Thor Straten, P; Tiitinen, A; Timpel, M; Toccoli, T; Torikai, K; Torres, W; Toscani, D; Trad, S; Tsai, HJ; Tseng, CP; Tucker, WJ; Um, W; Vallejo-Torres, L; van den Broek, M; Van den Heuvel, L; van der Woude, LN; van Maris, AJA; Van Schepdael, A; Vank, C; Verucchi, R; Vigo, JM; Viñas, C; Vogt, TJ; Vuong, C; Wai, H; Wang, B; Wang, D; Wang, H; Wang, JJ; Wang, K; Wang, L; Wang, Q; Wang, YR; Watanabe, S; Watters, AK; Weerasekera, MM; Wei, L; Wheeler, DA; Wiegand, I; Wifling, D; Wijesinghe, GK; Winiczenko, R; Wolker, T; Wu, J; Wu, TC; Wu, YY; Xie, P; Xie, YP; Xu, A; Xu, E; Xu, L; Xu, Z; Yamaguchi, M; Yang, A; Yang, G; Yang, J; Yang, TM; Yang, W; Yang, Y; Yarema, KJ; Yesiltepe, M; Yi, KJ; Yigit, N; Yim, UH; Yin, B; Yu, S; Zengin, G; Zhang, B; Zhang, C; Zhang, GR; Zhang, H; Zhang, J; Zhang, L; Zhang, TY; Zhang, X; Zhang, Y; Zhang, YX; Zhao, H; Zhao, JC; Zhao, Z; Zheng, R; Zhou, W; Zorn Morales, N | 1 |
| Almeida, A; Beach, CL; Fenaux, P; Giagounidis, A; Santini, V; Skikne, B; Tu, N; Weaver, J | 1 |
23 review(s) available for thalidomide and losartan potassium
| Article | Year |
|---|---|
Smoldering, asymptomatic stage 1, and indolent myeloma.
Topics: Alkylating Agents; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Diet Therapy; Diphosphonates; Erythropoietin; Humans; Multiple Myeloma; Neoplasm Staging; Pamidronate; Thalidomide; Treatment Outcome | 2000 |
Waldenström's macroglobulinaemia: current therapy and future approaches.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Erythropoietin; Humans; Interferon-alpha; Plasmapheresis; Prognosis; Purine Nucleotides; Splenectomy; Thalidomide; Waldenstrom Macroglobulinemia | 2002 |
Therapy strategies for multiple myeloma: current status.
Topics: Adjuvants, Immunologic; Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Erythropoietin; Glucocorticoids; Growth Inhibitors; Humans; Immunosuppressive Agents; Middle Aged; Multiple Myeloma; Oxides; Peripheral Blood Stem Cell Transplantation; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Transplantation, Homologous | 2003 |
Recent developments and future directions in the treatment of multiple myeloma.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Clinical Trials as Topic; Cysteine Endopeptidases; Diphosphonates; Doxorubicin; Erythropoietin; Etoposide; Forecasting; Humans; Interferons; Multienzyme Complexes; Multiple Myeloma; Organometallic Compounds; Organophosphorus Compounds; Oxides; Peripheral Blood Stem Cell Transplantation; Proteasome Endopeptidase Complex; Thalidomide; Tissue Extracts | 2003 |
Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Erythropoietin; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Myelodysplastic Syndromes; Thalidomide; Vascular Endothelial Growth Factor A | 2004 |
Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Topics: Anemia, Hypochromic; Azacitidine; Bone Marrow; Chromosome Aberrations; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Erythropoiesis; Erythropoietin; Gene Deletion; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Thalidomide | 2006 |
Strategies for achieving transfusion independence in myelodysplastic syndromes.
Topics: Anemia; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Drug Costs; Erythrocyte Transfusion; Erythropoietin; Health Services Needs and Demand; Humans; Immunosuppressive Agents; Informed Consent; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Quality of Life; Thalidomide; Treatment Outcome | 2007 |
Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
Topics: Anemia; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Delivery Systems; Erythropoiesis; Erythropoietin; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Recombinant Proteins; Thalidomide; Treatment Outcome | 2006 |
Risk-based management of myelodysplastic syndrome.
Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles | 2007 |
Myelofibrosis: biology and treatment options.
Topics: Benzamides; Chronic Disease; Darbepoetin alfa; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Piperazines; Primary Myelofibrosis; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Recombinant Proteins; Splenectomy; Thalidomide | 2007 |
[Development trend in new therapeutic approaches for anemia].
Topics: Anemia; Benzoates; Clinical Trials as Topic; Darbepoetin alfa; Deferasirox; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Lenalidomide; Myelodysplastic Syndromes; Neoplasms; Thalidomide; Triazoles | 2008 |
Myelodysplastic syndromes: biology and treatment.
Topics: Antineoplastic Agents; Blood Transfusion; Chromosomes, Human, Pair 5; Disease Progression; Erythropoietin; Female; Humans; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Male; Myelodysplastic Syndromes; Recombinant Proteins; Sequence Deletion; Thalidomide; World Health Organization | 2009 |
How I treat patients with myelodysplastic syndromes.
Topics: Acute Disease; Aged; Azacitidine; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Decitabine; Disease Progression; DNA Methylation; Erythropoietin; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid; Myelodysplastic Syndromes; Severity of Illness Index; Thalidomide; Transplantation, Homologous | 2009 |
[Novel therapeutic agents for myelodysplastic syndrome].
Topics: Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Decitabine; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Humans; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide | 2009 |
Pharmacotherapy of myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; DNA Methylation; Drug Approval; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; United States; United States Food and Drug Administration | 2010 |
Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Epoetin Alfa; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Recombinant Proteins; Thalidomide; Transplantation, Homologous | 2011 |
Renal crescentic alpha heavy chain deposition disease: a report of 3 cases and review of the literature.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cutis Laxa; Dexamethasone; Diabetic Nephropathies; Erythropoietin; Fatal Outcome; Female; Heavy Chain Disease; Hematuria; Humans; Hypertension, Renal; Immunoglobulin alpha-Chains; Immunoglobulin gamma-Chains; Immunoglobulin mu-Chains; Kidney Glomerulus; Male; Multiple Myeloma; Paraproteinemias; Proteinuria; Pyrazines; Thalidomide; Urticaria; Vasculitis, Leukocytoclastic, Cutaneous | 2011 |
Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemical and Drug Induced Liver Injury; Darbepoetin alfa; Diazepam; Erythropoietin; Fatal Outcome; Humans; Jaundice, Obstructive; Liver Function Tests; Male; Melphalan; Multiple Myeloma; Omeprazole; Pneumonia; Polypharmacy; Prednisolone; Thalidomide | 2012 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
The myelodysplastic syndromes: the era of understanding.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Erythropoietin; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Myelodysplastic Syndromes; Neoplasm Proteins; Prognosis; Spliceosomes; Thalidomide; Transplantation, Homologous | 2015 |
Does anything work for anaemia in myelofibrosis?
Topics: Androgens; Anemia; Blood Transfusion; Erythropoietin; Hematinics; Humans; Immunosuppressive Agents; Interferons; Lenalidomide; Nitriles; Oxymetholone; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Thalidomide | 2014 |
[Treatment of MDS].
Topics: Allografts; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Autografts; Azacitidine; Enzyme Inhibitors; Erythrocyte Transfusion; Erythropoietin; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Immunologic Factors; Immunosuppressive Agents; Induction Chemotherapy; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; Transplantation Conditioning | 2014 |
Current treatment algorithm for the management of lower-risk MDS.
Topics: Algorithms; Allografts; Erythrocyte Transfusion; Erythropoietin; Hematinics; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Stem Cell Transplantation; Thalidomide; Transforming Growth Factor beta | 2017 |
8 trial(s) available for thalidomide and losartan potassium
| Article | Year |
|---|---|
Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha.
Topics: Aged; Anticoagulants; Darbepoetin alfa; Drug Therapy, Combination; Erythropoietin; Heparin, Low-Molecular-Weight; Humans; Immunosuppressive Agents; Middle Aged; Myelodysplastic Syndromes; Pulmonary Embolism; Thalidomide; Thromboembolism; Venous Thrombosis | 2003 |
Combined treatment with thalidomide, corticosteroids, and erythropoietin in patients with idiopathic myelofibrosis.
Topics: Adrenal Cortex Hormones; Child, Preschool; Drug Therapy, Combination; Erythropoietin; Female; Humans; Infant; Male; Primary Myelofibrosis; Remission Induction; Thalidomide; Treatment Outcome | 2005 |
Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes.
Topics: Adult; Aged; Anemia; Drug Therapy, Combination; Erythropoietin; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Recombinant Proteins; Thalidomide; Treatment Outcome | 2006 |
Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Drug Administration Schedule; Drug Therapy, Combination; Erythropoietin; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins; Risk; Severity of Illness Index; Thalidomide; Thrombocytopenia; Treatment Outcome | 2012 |
Effects of exercise on fatigue, sleep, and performance: a randomized trial.
Topics: Adult; Affect; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Epoetin Alfa; Erythropoietin; Exercise; Fatigue; Female; Home Care Services; Humans; Male; Middle Aged; Models, Biological; Motor Activity; Multiple Myeloma; Muscular Atrophy; Peripheral Blood Stem Cell Transplantation; Polysomnography; Recombinant Proteins; Resistance Training; Sleep Disorders, Intrinsic; Thalidomide; Walking | 2012 |
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.
Topics: Aged; Anemia; Angiogenesis Inhibitors; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Therapy, Combination; Erythropoietin; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Staging; Prognosis; Prospective Studies; Risk Factors; Thalidomide | 2016 |
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.
Topics: Aged; Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Chromosome Deletion; Chromosomes, Human, Pair 5; Clonal Evolution; Clone Cells; DNA Mutational Analysis; Erythropoietin; Female; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; Treatment Outcome | 2016 |
Topics: Activities of Daily Living; Acute Disease; Adalimumab; Adaptation, Physiological; Adenosine Triphosphate; Adipose Tissue; Administration, Intravaginal; Adolescent; Adsorption; Adult; Adverse Childhood Experiences; Age Distribution; Age Factors; Aged; Aged, 80 and over; Air Pollution, Indoor; Aldehyde Oxidase; Alginates; Alloys; alpha-Globins; Aluminum Hydroxide; Alveolar Bone Loss; Anaerobiosis; Anesthesia, General; Anesthetics; Animals; Anovulation; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Bacillus cereus; Bacterial Typing Techniques; Bacteroidetes; Base Composition; Biocompatible Materials; Biofilms; Biological Availability; Biological Transport; Biosensing Techniques; Bipolar Disorder; Blood Glucose; Body Mass Index; Bone Regeneration; Boranes; Brachial Artery; Butyric Acid; Candida albicans; Carbon; Carcinoembryonic Antigen; Cell Differentiation; Cell Line, Tumor; Cell Respiration; Cell Survival; Cells, Cultured; Cerebrovascular Circulation; Charcoal; Child; Child Health; China; Chloride Channels; Chlorides; CHO Cells; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromium; Chronic Disease; Chronic Periodontitis; Circular Dichroism; Cities; Cohort Studies; Comamonadaceae; Comorbidity; Coronary Artery Disease; Corrosion; Cricetinae; Cricetulus; Cross Infection; Cross-Sectional Studies; Crowding; Culture Media; Cytokines; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetes, Gestational; Diarylheptanoids; Diclofenac; Disability Evaluation; Diterpene Alkaloids; DNA; DNA Mutational Analysis; DNA, Bacterial; Drug Liberation; Drug Resistance, Multiple, Bacterial; Electrochemical Techniques; Electrodes; Electrolytes; Endothelium, Vascular; Enterococcus faecalis; Epithelial Cell Adhesion Molecule; Epithelial Cells; Erbium; Erythropoietin; Ethanol; Ethylenediamines; Fast Foods; Fatty Acids; Female; Fermentation; Ferric Compounds; Fibroblasts; Flavobacteriaceae; Fluorides; Fluorodeoxyglucose F18; Food Microbiology; Formaldehyde; Furaldehyde; Gamma Cameras; Gene Expression; Geologic Sediments; Glucose Tolerance Test; Glycated Hemoglobin; Glycolipids; Glycosylation; Gracilaria; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Guanine; Health Surveys; HeLa Cells; Hemoglobins, Abnormal; Hexosamines; High Fructose Corn Syrup; High-Intensity Interval Training; Hip Fractures; Hippocampus; HLA-B27 Antigen; Hospitalization; Housing; Humans; Hydrogen-Ion Concentration; Hydrolysis; Hydroxides; Hypercapnia; Hypertension; Hypocreales; Hypromellose Derivatives; Image Processing, Computer-Assisted; Incidence; Indole Alkaloids; Indonesia; Inflammation Mediators; Infrared Rays; Insulin Resistance; Intercalating Agents; Ion Transport; Ionophores; Japan; Kinetics; Kluyveromyces; Letrozole; Linear Models; Lipopolysaccharides; Liposomes; Liver; Lung Diseases; Magnesium Hydroxide; Magnetic Resonance Spectroscopy; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice, Inbred BALB C; Microbial Sensitivity Tests; Microbial Viability; Microscopy, Electron, Transmission; Middle Aged; Mitochondria; Mitochondria, Muscle; Molecular Docking Simulation; Molecular Structure; Muscle, Skeletal; Mutant Proteins; Mutation; Mutation, Missense; Nanocomposites; Nanoparticles; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Nucleic Acid Hybridization; Obesity; Occupational Exposure; Oceans and Seas; Odds Ratio; Organometallic Compounds; Osteogenesis; Ovulation Induction; Oxidation-Reduction; Particle Size; Periodontal Ligament; Permeability; Phaseolus; Phenotype; Philippines; Phosphatidylethanolamines; Phospholipids; Photochemical Processes; Phylogeny; Pichia; Pigmentation; Plant Extracts; Polycystic Ovary Syndrome; Polysaccharides; Postprandial Period; Pregnancy; Pregnancy Rate; Prevalence; Product Surveillance, Postmarketing; Progesterone; Progestins; Protein Engineering; Pseudomonas aeruginosa; Psoriasis; Public Facilities; Rats; Rats, Wistar; Receptors, Thyrotropin; Recombinant Proteins; Reproducibility of Results; Republic of Korea; Retrospective Studies; Rhodobacteraceae; Risk; Risk Assessment; Risk Factors; RNA, Ribosomal, 16S; ROC Curve; Saccharomyces cerevisiae; Salinity; Saliva; Seawater; Seaweed; Sensitivity and Specificity; Sequence Analysis, DNA; Sex Factors; Silver Compounds; Smokers; Social Class; Socioeconomic Factors; Soil Microbiology; Solubility; Soy Foods; Spectrometry, Mass, Electrospray Ionization; Spondylitis, Ankylosing; Staphylococcus aureus; Static Electricity; Steroids; Strontium; Sucrose; Surface Properties; Survival Rate; Sweden; Swine; Synapses; Synchrotrons; Tandem Mass Spectrometry; Tannins; Tea; Temperature; Terpenes; Thalidomide; Thermodynamics; Thiadiazoles; Thyroid Cancer, Papillary; Thyroid Neoplasms; Thyroidectomy; Time Factors; Tissue Distribution; Titanium; Toilet Facilities; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Ubiquinone; Urinary Tract Infections; Vaginal Creams, Foams, and Jellies; Venezuela; Vitamin K 2; Waist Circumference; Waste Disposal, Fluid; Wastewater; Water Microbiology; Water Pollutants, Chemical; Whole Body Imaging; X-Ray Diffraction; Young Adult; Ytterbium; Yttrium; Yttrium Radioisotopes; Zinc Compounds | 2018 |
20 other study(ies) available for thalidomide and losartan potassium
| Article | Year |
|---|---|
Erythropoietin release in renal allografted baboons, with and without immunosuppression.
Topics: Animals; Antibodies, Anti-Idiotypic; Azathioprine; Biological Assay; Chloroquine; Cortisone; Cyclophosphamide; Erythropoietin; Female; Goats; Haplorhini; Immunization, Passive; Immunosuppressive Agents; Iron Isotopes; Kidney; Kidney Transplantation; Male; Mice; Ribonucleases; Thalidomide; Tissue Extracts; Transplantation Immunology; Transplantation, Homologous | 1970 |
Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Blood Transfusion; Combined Modality Therapy; Drug Evaluation; Erythropoietin; Female; Fetal Hemoglobin; Humans; Male; Middle Aged; Thalidomide; Treatment Outcome | 2002 |
Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents.
Topics: Blood Transfusion; Disease Management; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Erythropoietin; Humans; Male; Middle Aged; Primary Myelofibrosis; Thalidomide; Treatment Outcome | 2003 |
Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Agents; Drug Synergism; Erythropoietin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recombinant Proteins; Risk; Thalidomide; Thrombosis; Venous Thrombosis; Warfarin | 2004 |
The 5q- syndrome.
Topics: Age Factors; Antigens, CD; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetics; Erythropoietin; Female; Gene Deletion; Genes, Tumor Suppressor; Humans; Immunosuppressive Agents; Lenalidomide; Male; Myelodysplastic Syndromes; Prognosis; Sex Factors; Thalidomide | 2004 |
Lenalidomide and venous thrombosis in multiple myeloma.
Topics: Anti-Inflammatory Agents; Dexamethasone; Drug Therapy, Combination; Erythropoietin; Humans; Lenalidomide; Multiple Myeloma; Multivariate Analysis; Thalidomide; Venous Thrombosis | 2006 |
Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States.
Topics: Antineoplastic Agents; Blood Transfusion; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Cost-Benefit Analysis; Decision Support Techniques; Erythropoietin; Humans; Lenalidomide; Medical Oncology; Models, Econometric; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Quality-Adjusted Life Years; Recombinant Proteins; Risk Factors; Thalidomide; United States | 2006 |
Deep vein thrombosis occurring on treatment of patients receiving thalidomide with erythropoietin.
Topics: Aged; Erythropoietin; Hematinics; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Risk Factors; Thalidomide; Treatment Outcome; Venous Thrombosis | 2007 |
Advances in MDS.
Topics: Antineoplastic Agents; Erythropoietin; Female; Granulocyte Precursor Cells; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Thalidomide | 2007 |
Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Erythropoietin; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide | 2008 |
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
Topics: Anemia; Antineoplastic Agents; Azacitidine; Cost of Illness; Costs and Cost Analysis; Darbepoetin alfa; Decision Support Techniques; Deferoxamine; Drug Costs; Drug Therapy; Epoetin Alfa; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Recombinant Proteins; Siderophores; Thalidomide; United States | 2008 |
Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Erythropoietin; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Thalidomide; Treatment Outcome | 2009 |
Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.
Topics: Aged, 80 and over; Anabolic Agents; Anemia, Refractory; Anemia, Sideroblastic; Antineoplastic Agents; Erythropoietin; Humans; Hypertension, Pulmonary; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Mutation; Pulmonary Embolism; Pyridoxine; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Thrombocytosis; Vitamin B Complex | 2010 |
Management of myelodysplastic syndromes in the geriatric patient.
Topics: Aged; Anemia; Antineoplastic Agents; Azacitidine; Decitabine; Erythrocyte Transfusion; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2009 |
Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Epoetin Alfa; Erythropoietin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recombinant Proteins; Risk Factors; Thalidomide; Venous Thromboembolism | 2012 |
[Myelodysplastic syndrome in the elderly: comprehensive geriatric assessment and therapeutic recommendations].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Decision Support Techniques; Deferoxamine; Erythropoietin; Health Status Indicators; Humans; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Siderophores; Thalidomide | 2012 |
Acquired EVI1 rearrangement involved in the transformation from 5q- syndrome to pre-B lymphocytic leukemia in a Chinese patient.
Topics: Adult; Anemia, Macrocytic; Blood Transfusion; Bone Marrow; Cell Differentiation; Cell Lineage; Chromosome Deletion; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 5; Disease Progression; DNA-Binding Proteins; Erythropoietin; Fatal Outcome; Fatigue; Humans; Immunophenotyping; Karyotype; Male; MDS1 and EVI1 Complex Locus Protein; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogenes; Testosterone; Thalidomide; Transcription Factors | 2012 |
Myelodysplastic syndrome.
Topics: Aged; Anemia, Macrocytic; Bone Marrow; Erythropoietin; Fatigue; Humans; Lenalidomide; Myelodysplastic Syndromes; Stem Cell Transplantation; Thalidomide | 2016 |
Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes.
Topics: Calgranulin B; Erythropoiesis; Erythropoietin; Hep G2 Cells; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Tumor Necrosis Factor-alpha | 2017 |
Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels.
Topics: Erythrocyte Transfusion; Erythropoietin; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2020 |